Journavx Market Access Strategy in Focus: What ...

By Rene Pretorius

March 17, 2025

Vertex Pharmaceuticals’ Journavx, a non-opioid pain medication, received
Pharmacy Benefit Managers Report Reveals Escalating Drug Costs and Calls for ...
Tariff Impact on Drugs: Navigating Challenges in the Generic and Biosimilar M...
Evolving Cervical Cancer Treatment: Innovations and Challenges
Medicare Drug Negotiations Target Ozempic and Ibrance for Price Cuts
Reevaluating NICE’s Cost-Effectiveness Thresholds: The QALY Debate
Improving Access to Trikafta for Cystic Fibrosis Patients in South Africa
CMS Price Negotiations: Bridging the Gap in US Drug Pricing
Access to Anti-Obesity Medication for Medicare and Medicaid
Sanofi’s 340B Rebate Model: A Joint Effort to Reform Drug Pricing Pract...
Lawsuits Challenge 340B Drug Pricing Program: Eli Lilly and J&J vs. HRSA
Leveraging Bayh-Dole Act March-In Rights to Reduce US Drug Prices
Overview of NICE’s Elranatamab Managed Access Agreement